Biologics CDMO FAQs Library

Yes, a CDMO can provide CMC reports, batch and method documentation, responses to technical questions, stability data, change assessments and lifecycle manufacturing support. The sponsor remains the applicant and owns the regulatory strategy and final submissions.

After manufacture, the CDMO completes testing, deviation assessment, batch review and agreed release documentation. It may supply Module 3 source content, validation summaries, facility information and subject-matter experts for agency questions or inspections. Ongoing stability studies support retest periods and shelf life, while change control manages scale, equipment, raw-material or method changes. Later campaigns may require process characterisation, validation, comparability and commercial supply planning. Selecting a partner that can support the next stage reduces the risk of rebuilding the CMC history after the first clinical batch.

Choose a CDMO by matching its demonstrated modality experience, equipment, scale, quality record, analytical depth, project team and availability to the programme’s next two milestones. A strong fit is more important than the broadest capability list.

Ask for examples that resemble the product, expression system, biosafety level and development stage rather than generic company claims. Confirm which activities are in-house, which are outsourced and who owns vendor management. Review the proposed team, governance cadence, escalation route and access to technical experts. Test whether the timeline includes method transfer, raw materials, quality review and release instead of only the manufacturing run. References, audit findings, inspection history and a technical due-diligence visit provide evidence beyond the sales presentation.

Involve a CDMO before the expression system, raw materials, analytical plan and scale-up assumptions are locked, ideally during lead selection or early CMC planning. Early engagement reduces the chance that research choices must be rebuilt for GMP. |

A short technical dialogue can identify whether the host, construct, process and assays are compatible with clinical manufacture. It can also expose long-lead cell banks, reference standards, resins, single-use components or biosafety approvals. The sponsor does not need a final process or complete data package to begin. Early planning can remain phase-appropriate and focus only on decisions that are difficult to reverse later. Waiting until a GMP slot is needed often leaves insufficient time for transfer, method readiness and quality release.

A first GMP batch can take roughly six to twelve months for a mature transferable process and twelve to twenty-four months or more when cell-line development, major process work or new analytical methods are required. These are planning ranges, not a slot or delivery commitment.

Microbial programmes with an established strain may sit at the shorter end, while a new stable CHO line or complex ATMP usually requires more development. The schedule includes technical assessment, contracting, materials, method transfer or development, engineering work, GMP readiness, manufacture, testing and quality release. Formal stability continues after batch release and supports later shelf-life claims. Facility adaptation, high containment or a difficult potency assay can extend the calendar beyond the typical range. The CDMO should provide a product-specific critical-path schedule after reviewing the data package.

One integrated CDMO can reduce handovers, duplicated studies and governance burden, while several specialists may provide deeper platform expertise or more capacity flexibility. The best model depends on technical fit, schedule, concentration risk and the sponsor’s ability to manage interfaces.

An integrated route can align expression, process, analytics and GMP decisions from the start and maintain one project history. It also creates dependency on one provider and may be weaker if a critical activity sits outside its core expertise. A specialist network can select the strongest provider for each stage but adds data transfer, material shipping, method bridging and contractual interfaces. The hidden time at each handover should be included in the comparison. A hybrid model works when one lead CDMO owns integration and qualified specialists cover clearly bounded gaps.

Timelines are affected by process maturity, assay readiness, cell-bank or seed status, raw-material lead times, biosafety, facility availability, engineering needs, GMP manufacture and quality release. The longest dependency, not the production run, usually sets the delivery date.

A project with a transferable process and qualified methods can progress faster than one that still needs expression-system or potency-assay development. Bespoke resins, single-use assemblies, reference standards and outsourced safety tests may have multi-month lead times. Deviations, out-of-specification investigations and failed acceptance criteria introduce uncertain delays. Running workstreams in parallel can shorten the calendar but increases the risk of repeating work after a change. A good schedule shows assumptions, decision gates, client inputs and float around high-uncertainty activities.

Chain of identity proves that the right starting material and product belong to the correct donor, patient or manufacturing lot, while chain of custody records who controlled the material at every step. Both rely on unique identifiers, reconciled records, controlled labelling and verified handovers.

Autologous products make patient-level identity especially critical, but allogeneic products also require complete donor, bank, batch and dose traceability. Electronic or paper systems must remain aligned across collection, shipment, receipt, manufacture, testing, storage and clinical delivery. Label design should prevent mix-ups while protecting personal data. Deviations such as damaged labels, temperature excursions or missed scans need predefined investigation and disposition rules. The logistics model might be challenged in a simulated workflow before patient material is placed at risk.

Cryopreservation can extend shelf life and reduces issues of thawing the material that may reduce viability, recovery or potency. The formulation, cooling rate, storage, transport and thaw procedure must therefore be developed as one controlled process.

Cryoprotectant concentration, cell density, container and hold time before freezing influence post-thaw performance. Controlled-rate freezing reduces uncontrolled ice formation, while vapour-phase liquid-nitrogen storage can maintain very low temperatures with continuous monitoring. Viability immediately after thaw may not capture delayed cell death or functional loss, so post-thaw potency and recovery are important. NorthX describes controlled-rate freezing, monitored vapour-phase storage and controlled shipment as part of its cell therapy capability.

Cell therapy scale-up increases the number of reproducible doses while maintaining viability, potency and safety. It may require larger or parallel culture systems, more automation, closed processing and a revised sampling and control strategy.

For adherent cells, scale-up may move from flasks to multilayer vessels, microcarriers or automated bioreactors. Suspension cells may move into bags or stirred systems, but shear, gas transfer and cell density still need product-specific control. Scale-out uses multiple parallel units and can preserve a familiar process, although it increases operational complexity and the number of connections and records. Scale-up can change cell residence time, mixing, nutrient exposure and harvest stress, any of which can affect function. Comparability data should therefore link process changes to the critical quality attributes of the cells were required.

A mature cell therapy process may require roughly six to twelve months or more for gap assessment, method transfer, engineering work, GMP preparation and batch release, a process needing redevelopment, new assays or facility adaptation can take longer. The production run itself is only one part of the timeline.

The schedule starts with process and analytical knowledge transfer, materials and equipment mapping, quality agreements and biosafety review. Engineering or demonstration runs are often needed to train operators and confirm closed connections, sampling, filling and cryopreservation. Method qualification, microbiological strategy and reference-material readiness can drive the critical path. Facility modifications or new automated equipment add qualification and regulatory activities. A credible plan separates technical transfer, GMP readiness, manufacture, testing, quality review and final release rather than presenting them as one date.

Cell therapy manufacturing converts donor- or patient-derived cells into a controlled medicinal product through isolation, expansion, activation or differentiation, harvest, formulation, filling, testing and storage. Because the cells are the product, the process must preserve identity, viability and biological function throughout.

The exact unit operations depend on the cell type and mechanism of action. Adherent cells may use flasks, multilayer systems or bioreactors, while suspension cells use different expansion and harvest technologies. Open manipulations require high-grade cleanroom controls, whereas validated closed systems can reduce contamination risk and support operation in a lower grade cleanroom. In-process monitoring tracks growth, phenotype, viability and critical culture conditions. The final product is released against product-specific tests and distributed under a controlled temperature and chain-of-custody strategy.

A cell therapy process change requires a risk-based comparability assessment to show that pre-change and post-change product remain sufficiently similar for the intended stage. The evidence may include analytical, functional, stability and, in some cases, non-clinical or clinical data.

Changes to cell source, media, culture system, scale, cryopreservation or site can alter cell phenotype and function. The assessment begins by identifying which critical quality attributes the change could affect. Side-by-side manufacturing and testing are strongest when representative pre-change material and sensitive assays are available. The later the development stage, the more consequential a poorly planned change can become. A lifecycle strategy should therefore anticipate commercial scale and supply needs before pivotal development locks in an unsustainable process.

Yes. Antibiotic marker-free systems can maintain expression without adding antibiotics to the production process, provided plasmid stability and productivity are demonstrated for the intended culture duration.

Avoiding antibiotic selection can simplify raw-material control and reduce concerns about antibiotic residues and resistance genes. It does not remove the need to confirm genetic stability, construct identity and retention through the production process. The host-vector system must remain productive under manufacturing conditions, not only during short screening cultures. NorthX’s enGenes pathway includes antibiotic marker-free production among the available expression-optimisation strategies. The choice should still be justified against product yield, process robustness and regulatory expectations for the programme.

Yes, an existing strain and process can be transferred for assessment, gap analysis, scale-up, analytical development, and GMP manufacturing rather than rebuilt automatically. The amount of redevelopment depends on the quality of the strain history, data package, and process fit with the receiving facility.

A transfer review normally covers construct identity, host provenance, cell-bank status, raw materials, process parameters, analytical methods and prior batch performance. NorthX can then identify which elements are ready to transfer and which create risks for scale, compliance or product quality. A well-documented process may move directly into confirmation or engineering work, while an unstable expression system or non-scalable purification step may need targeted optimisation. The goal is to preserve useful prior knowledge rather than repeat work without reason. Clear transfer acceptance criteria make the schedule and responsibilities visible to both teams.

Yes, purification and analytics work can start with representative small-scale material while fermentation optimisation continues. Parallel downstream development and analytical work can shorten the schedule, provided later material is shown to be representative enough for each study’s purpose.

Early material can support resin screening, clarification studies, impurity-method development and a first assessment of product stability. This exposes downstream bottlenecks before the upstream process is locked. The trade-off is that a major change in expression level, cellular location or impurity profile may require some studies to be repeated. Teams should therefore define which results are exploratory and which will support later GMP decisions. A shared sample plan and change-control logic keep parallel work fast without creating hidden rework.

Endotoxin is controlled through strain and process design, contamination-controlled manufacturing, purification steps with demonstrated clearance and a validated or qualified assay at appropriate stages. The acceptable limit is product- and dose-specific, so it must be set from the intended route and maximum patient exposure.

E. coli lipopolysaccharide can enter the process during cell disruption and may associate strongly with the target protein. Upstream conditions and harvest design can reduce the impurity burden before chromatography begins. Downstream strategies may combine phase separation, ion exchange, membrane-based operations or other product-specific steps, because no single method works for every molecule. In-process testing shows where endotoxin is removed and prevents the final release test from becoming the first sign of a problem. For OMV products, lipopolysaccharide may be part of the product platform, but its composition and biological activity still require deliberate control.

Choose E. coli (microbial) when possible. It is faster and cheaper but not suitable if the product requires complex post-translational modifications. Choose CHO when glycosylation, native secretion, or mammalian folding is important to product activity, safety, or half-life.

E. coli programmes can move from sequence to expression data quickly and usually use simpler media and shorter culture cycles. CHO development takes longer because it commonly includes stable cell-line generation, clone selection, and cell-bank creation. The apparent lower cost of E. coli can disappear if extensive refolding or impurity clearance is required, while CHO may justify its higher upstream complexity by secreting a correctly folded product into the culture medium. The decision should therefore compare product quality, recovery yield, downstream complexity, regulatory history and cost per usable dose rather than titre alone. Running a small feasibility study before committing to one platform can prevent later redevelopment.

Read more about navigating the complexities of microbial and mammalian manufacturing

The integrated enGenes-NorthX Biologics gene-to-GMP pathway for E. coli expression development is designed to deliver decision-grade expression data within weeks and can remove an estimated three to six months compared with a fragmented development-to-GMP handover. The total time to a released GMP batch still depends on molecule complexity, process maturity, analytical readiness, and manufacturing-slot availability.

Early work for E. coli expression development, normally covers construct and host screening, soluble-expression assessment, and initial product-quality testing. Process development then establishes fermentation, harvest, purification, and formulation conditions that can be reproduced at the intended scale. Cell-bank preparation and testing, method qualification or validation, raw-material sourcing, batch documentation, GMP manufacture, and quality release add separate schedule-critical activities. Refolding, difficult impurity clearance, or a new potency assay can extend the critical path. A credible timeline should therefore show dependencies and decision points, not only a single target date.

Yes-NorthX describes development and GMP manufacturing support for bacterial OMVs/EVs and mammalian EVs, including microbial and mammalian processing and product-specific analytics. The exact scope and route to GMP are assessed for each source, payload and development stage.

NorthX’s has microbial experience relevant to OMV/EV strains, fermentation, purification and GMP work. Its mammalian capabilities include adherent systems such as fixed-bed and hollow-fibre approaches that may support selected EV-producing cells. NorthX also reports active investment in OMV/EV analytical platform development and an intention to extend relevant learning to mammalian EVs. Because the field lacks one universal manufacturing and release platform, the project plan must remain product-specific. An initial technical review should confirm biosafety, equipment fit, analytical gaps, material needs and the evidence required for the next regulatory milestone.

Manufacturing-scale purification normally combines clarification, filtration, concentration or diafiltration and one or more chromatographic or size-based operations. The sequence is product-specific because recovery, impurity clearance and vesicle integrity trade off against one another.

Low-speed clarification and depth or membrane filtration first remove cells and larger debris. Tangential-flow filtration can concentrate vesicles and exchange buffer, but membrane choice and operating conditions affect recovery and aggregation. Chromatography or other orthogonal separations may reduce soluble proteins, nucleic acids, free payload and unwanted particles. Research ultracentrifugation can be useful for development but is often difficult to scale, automate and validate for routine manufacture. Each step should be evaluated using mass balance, particle recovery, impurity clearance and retained biological activity.

OMV lipopolysaccharide is controlled through source-strain design, culture and harvest conditions, purification, compositional testing and relevant biological assays. Because lipopolysaccharide may contribute to both activity and reactogenicity, the goal is a justified and consistent profile rather than indiscriminate removal.

Genetic changes can reduce or alter activity, but they may also affect strain growth, vesicle yield and product composition. Process conditions influence the amount and type of bacterial material packaged into or associated with the vesicles. Standard endotoxin assays may not fully predict the biological behaviour of a complex OMV product, so additional pyrogenicity or cell-based testing may be needed. Dose and route of administration determine the clinical relevance of the measured activity. The control strategy should connect strain genetics, process parameters, composition, potency and safety data.

Sterility risk is managed through controlled source materials, closed or contamination-controlled processing where possible, bioburden monitoring, validated sterile filtration when the product allows it and aseptic filling. If vesicle size or formulation prevents a final sterilising filter, upstream aseptic controls become even more important.

The process design should identify how contamination is prevented or detected. Mammalian cell substrates also require an adventitious-agent strategy, while bacterial products need controls that distinguish intended organisms or components from contamination. Filter compatibility must be demonstrated because vesicles can be retained, damaged or change size distribution. Methods are selected according to sample constraints and regulatory expectations. Hold times, storage, transport and container closure are part of the same sterility-assurance strategy.

Choose a mammalian EV platform when cell-derived delivery or signalling biology is central to the product, and evaluate an OMV platform when immune stimulation, antigen display or bacterial scalability is advantageous. The choice must match the intended mechanism, safety profile, payload and route of administration. Note that bacterial EVs can have properties similar to bacterial OMVs and/or Mammalian EVs.

Mammalian EVs can carry proteins, lipids and nucleic acids in a biologically derived membrane, but their heterogeneity and often modest productivity make scale-up challenging. OMVs can provide natural pathogen-associated signals and dense antigen presentation, which is useful for vaccines and immunotherapy but requires deliberate control of reactogenic components such as lipopolysaccharide. Source-cell or source-strain engineering can alter yield, cargo and targeting for either platform. The purification process must preserve function while removing product- and process-related impurities. A feasibility package should compare potency per dose, recovery, consistency, safety and cost at the intended scale.

EV or OMV potency should measure a biological function related to the proposed mechanism of action, such as target-cell uptake, cargo delivery, immune activation or a downstream functional response. Particle count alone is not a potency assay.

An early programme may use a matrix of complementary assays while the mechanism is still being refined. A cell-based assay often provides biological relevance but can be variable and slow, so supporting binding, enzymatic or molecular assays may strengthen the control strategy. The assay must distinguish active product from degraded, empty or compositionally altered particles. Reference material and system-suitability controls are especially important for heterogeneous vesicle products. Starting potency development early reduces the risk that an otherwise manufacturable process reaches GMP without a release-ready functional method.

Purification is typically designed backwards from the required product quality, as higher quality demands typically require more purification steps. The process combines operations that recover the product while clearing host-cell proteins, DNA, aggregates, endotoxin where relevant, and other process-related impurities.

An affinity capture step can be efficient when a suitable ligand or tag is available, but commercial products may require a tag-free or platform-specific strategy. Ion exchange, hydrophobic interaction, multimodal, and size-based separations are selected according to the molecule’s charge, size, stability, and impurity profile. Ultrafiltration and diafiltration concentrate the product and exchange it into the required buffer. Each additional unit operation may improve clearance but can reduce yield, lengthen processing, and increase cost. The aim is therefore the minimum robust sequence that meets quality requirements at scale, not the largest possible number of purification steps.

The best expression system is selected by matching the protein’s structural and functional requirements with host capability, scalable recovery and long-term cost. Glycosylation, folding, disulphide bonds, toxicity, secretion and target dose usually drive the decision. Ultimately a range of different host and systems might need to be tested.

E. coli can offer rapid, cost-efficient production when complex mammalian processing is not required. CHO is often chosen for antibodies and glycoproteins that need mammalian folding and glycosylation, while HEK293 may suit selected complex proteins or viral applications. A system with the highest expression signal may still lose on usable yield if purification, refolding or product heterogeneity is difficult. Regulatory history, platform licences, cell-bank strategy and facility fit also affect the choice. Feasibility data should compare active purified product and relevant quality attributes rather than total expression alone.

A new programme can range from several months for a tractable microbial product with a mature analytical strategy to a year for a new stable mammalian cell line and full GMP package. The critical path is set by expression-system readiness, cell banking, process complexity, assay development, raw materials and manufacturing access.

Early non-GMP material may be available in weeks or a few months, but it is not the same milestone as a released clinical batch. Stable CHO clone selection alone often takes about four to six months before banking and full characterisation are complete. A microbial route can be shorter, and NorthX states that its integrated enGenes pathway can avoid three to six months of handover time compared with fragmented delivery. Potency assays, viral-safety work, stability data or hard-to-source materials can become longer lead-time items than the production run itself. A realistic schedule should show decision points, parallel workstreams and release activities separately.

Titre is the amount of product present in the culture or fermentation harvest, purity is the proportion of the target protein in the tested sample, and overall yield is the amount of acceptable product recovered after the full process. A high titre does not guarantee a high final yield or a suitable product.

Titre is useful for upstream comparison but does not account for insoluble, inactive or difficult-to-purify material. Step yield shows recovery across one unit operation, while overall process yield multiplies losses across harvest, purification and formulation. Purity must be interpreted together with potency, aggregates, variants and residual impurities. An apparent upstream improvement can increase downstream loss if it also increases aggregation or contaminant burden. Process decisions should therefore use grams of released-quality product per batch or per unit cost where possible, not titre alone.

Recombinant protein manufacturing uses an engineered host cell to produce a defined protein from an introduced genetic sequence. The process includes expression-system development, cell culture or fermentation, harvest, purification, formulation, testing and, when required, GMP manufacture.

Common hosts include E. coli for many non-glycosylated proteins and CHO or HEK293 cells for more complex mammalian proteins. The manufacturing process must consistently deliver the intended product with the correct structure, activity and impurity profile, not simply a high amount of protein. Upstream and downstream steps are therefore developed as one connected process. Analytical methods track identity, purity, potency, content, product variants and process-related impurities. For clinical use, cell-bank control, raw-material traceability, batch records, release testing and stability data become part of the CMC package.

Non-GMP material may be suitable for research, assay development or selected non-clinical work, while GMP material is manufactured and controlled under an approved pharmaceutical quality system for its intended clinical or commercial use. The difference is the controlled system and documented evidence, not simply a final purity result.

GMP manufacture requires approved instructions, qualified facilities and equipment, trained personnel, controlled materials, deviation handling, data integrity and quality-unit oversight. The batch is tested against approved specifications and released through a defined quality process. Phase-appropriate GMP allows the depth of control and validation to grow with product knowledge and patient exposure, but it does not mean that core requirements can be ignored. Using research-grade starting materials or methods too late can force bridging, replacement or repeated studies. The material grade should therefore be matched to the exact study, jurisdiction and development stage before production begins.